Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.58 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969757 | 0.95 | DPP4 (0.59) | DPP4FAPALDH1A1LMNAMAPT | |
| SCHEMBL3968845 | 0.90 | DPP4 (0.61) | DPP4FAPALDH1A1LMNAMAPT | |
| SCHEMBL3970984 | 0.90 | DPP4 (0.61) | DPP4FAPALDH1A1LMNAMAPT | |
| SCHEMBL3975838 | 0.90 | DPP4 (0.61) | DPP4FAPALDH1A1LMNAMAPT | |
| SCHEMBL3969251 | 0.89 | DPP4 (0.62) | DPP4FAPALDH1A1LMNAMAPT | |
| SCHEMBL3971400 | 0.88 | DPP4 (0.63) | DPP4FAPALDH1A1LMNAMAPT | |
| SCHEMBL3969560 | 0.88 | DPP4 (0.63) | DPP4FAPALDH1A1LMNAMAPT | |
| SCHEMBL3974557 | 0.88 | DPP4 (0.63) | DPP4FAPALDH1A1LMNAMAPT | |
| SCHEMBL3969502 | 0.88 | DPP4 (0.59) | DPP4FAPALDH1A1LMNAMAPT | |
| SCHEMBL3970559 | 0.88 | DPP4 (0.59) | DPP4FAPALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569574-B2 | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-04 | — | — | US | claimed |
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | claimed |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | claimed |
| US-7569574-B2 | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-04 | — | — | US | disclosed |
| EP-1532150-B1 | NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 36/4885ALDH1A1 187/4885 |
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 48/4885ALDH1A1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.